AR114283A1 - Receptores quiméricos de dll3 y métodos para su uso - Google Patents

Receptores quiméricos de dll3 y métodos para su uso

Info

Publication number
AR114283A1
AR114283A1 ARP190100947A ARP190100947A AR114283A1 AR 114283 A1 AR114283 A1 AR 114283A1 AR P190100947 A ARP190100947 A AR P190100947A AR P190100947 A ARP190100947 A AR P190100947A AR 114283 A1 AR114283 A1 AR 114283A1
Authority
AR
Argentina
Prior art keywords
dll3
methods
receptors
chemeric
antigen
Prior art date
Application number
ARP190100947A
Other languages
English (en)
Spanish (es)
Inventor
Lawren Wu
Ryan B Case
Christopher Murawsky
Melissa Thomas
Michael John Giffin
Original Assignee
Amgen Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Amgen Inc filed Critical Amgen Inc
Publication of AR114283A1 publication Critical patent/AR114283A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/30—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/10—Cellular immunotherapy characterised by the cell type used
    • A61K40/11—T-cells, e.g. tumour infiltrating lymphocytes [TIL] or regulatory T [Treg] cells; Lymphokine-activated killer [LAK] cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/30—Cellular immunotherapy characterised by the recombinant expression of specific molecules in the cells of the immune system
    • A61K40/31—Chimeric antigen receptors [CAR]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/40—Cellular immunotherapy characterised by antigens that are targeted or presented by cells of the immune system
    • A61K40/41—Vertebrate antigens
    • A61K40/42—Cancer antigens
    • A61K40/428—Undefined tumor antigens, e.g. tumor lysate or antigens targeted by cells isolated from tumor
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70503—Immunoglobulin superfamily
    • C07K14/70517—CD8
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70503—Immunoglobulin superfamily
    • C07K14/70521—CD28, CD152
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70578—NGF-receptor/TNF-receptor superfamily, e.g. CD27, CD30, CD40, CD95
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C12N15/86—Viral vectors
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0652—Cells of skeletal and connective tissues; Mesenchyme
    • C12N5/0656—Adult fibroblasts
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K40/00
    • A61K2239/31—Indexing codes associated with cellular immunotherapy of group A61K40/00 characterized by the route of administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K40/00
    • A61K2239/38—Indexing codes associated with cellular immunotherapy of group A61K40/00 characterised by the dose, timing or administration schedule
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K40/00
    • A61K2239/46—Indexing codes associated with cellular immunotherapy of group A61K40/00 characterised by the cancer treated
    • A61K2239/55—Lung
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70503—Immunoglobulin superfamily
    • C07K14/7051—T-cell receptor (TcR)-CD3 complex
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
    • C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
    • C07K2317/622—Single chain antibody (scFv)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
    • C07K2319/03—Fusion polypeptide containing a localisation/targetting motif containing a transmembrane segment
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/33—Fusion polypeptide fusions for targeting to specific cell types, e.g. tissue specific targeting, targeting of a bacterial subspecies
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2740/00—Reverse transcribing RNA viruses
    • C12N2740/00011—Details
    • C12N2740/10011—Retroviridae
    • C12N2740/15011—Lentivirus, not HIV, e.g. FIV, SIV
    • C12N2740/15041—Use of virus, viral particle or viral elements as a vector

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Genetics & Genomics (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Epidemiology (AREA)
  • Zoology (AREA)
  • Cell Biology (AREA)
  • Engineering & Computer Science (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Toxicology (AREA)
  • Biomedical Technology (AREA)
  • Biotechnology (AREA)
  • Wood Science & Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • General Engineering & Computer Science (AREA)
  • Microbiology (AREA)
  • Physics & Mathematics (AREA)
  • Virology (AREA)
  • Rheumatology (AREA)
  • Plant Pathology (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
ARP190100947A 2018-04-10 2019-04-10 Receptores quiméricos de dll3 y métodos para su uso AR114283A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US201862655725P 2018-04-10 2018-04-10

Publications (1)

Publication Number Publication Date
AR114283A1 true AR114283A1 (es) 2020-08-12

Family

ID=66248863

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP190100947A AR114283A1 (es) 2018-04-10 2019-04-10 Receptores quiméricos de dll3 y métodos para su uso

Country Status (27)

Country Link
US (1) US12012462B2 (https=)
EP (1) EP3773912A1 (https=)
JP (1) JP7479290B2 (https=)
KR (1) KR102951376B1 (https=)
CN (1) CN112334193A (https=)
AR (1) AR114283A1 (https=)
AU (2) AU2019251473A1 (https=)
BR (1) BR112020020857A2 (https=)
CA (1) CA3095920A1 (https=)
CL (3) CL2020002613A1 (https=)
CO (1) CO2020013392A2 (https=)
CR (1) CR20200539A (https=)
EA (1) EA202092417A1 (https=)
IL (1) IL277735A (https=)
JO (1) JOP20200259A1 (https=)
MA (1) MA52203A (https=)
MX (1) MX2020010753A (https=)
MY (1) MY203383A (https=)
PE (1) PE20211396A1 (https=)
PH (1) PH12020551671A1 (https=)
SA (1) SA520420301B1 (https=)
SG (1) SG11202009923TA (https=)
TW (1) TWI842703B (https=)
UA (1) UA129466C2 (https=)
UY (1) UY38182A (https=)
WO (1) WO2019200007A1 (https=)
ZA (1) ZA202006943B (https=)

Families Citing this family (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DK3661954T3 (da) 2017-08-03 2022-04-19 Amgen Inc Interleukin-21-muteiner og fremgangsmåder til behandling
TW201930344A (zh) 2018-01-12 2019-08-01 美商安進公司 抗ｐｄ-１抗體及治療方法
CA3146019A1 (en) 2019-07-17 2021-01-21 Nanjing Legend Biotech Co., Ltd. Anti-dll3 chimeric antigen receptors and uses thereof
CA3160759A1 (en) * 2019-12-05 2021-06-10 Vycellix, Inc. Modulators of the immune escape mechanism for universal cell therapy
WO2021183861A1 (en) 2020-03-12 2021-09-16 Amgen Inc. Method for treatment and prophylaxis of crs in patients comprising a combination of bispecifc antibodies binding to cds x cancer cell and tnfalpha or il-6 inhibitor
US12606635B2 (en) 2020-03-12 2026-04-21 Nanjing Legend Biotech Co., Ltd. Glypican-2-binding moieties, chimeric antigen receptors and uses thereof
CN117083067A (zh) * 2021-04-02 2023-11-17 南京传奇生物科技有限公司 工程化的免疫细胞及其用途
CN117529337A (zh) * 2021-05-08 2024-02-06 上海齐鲁制药研究中心有限公司 针对dll3的结合分子及其应用
US20240317856A1 (en) * 2021-05-10 2024-09-26 Amgen Inc. Dosing regimen for combination therapy targeting dll3 and pd-1
CA3225252A1 (en) 2021-07-14 2023-01-19 Jordan JARJOUR Engineered t cell receptors fused to binding domains from antibodies
AU2023228374A1 (en) 2022-03-03 2024-09-19 Cambridge Enterprise Limited Therapeutic antibodies
CN119546328A (zh) 2022-04-08 2025-02-28 再生元制药公司 多部分受体和信号传导复合物
WO2023199069A1 (en) 2022-04-14 2023-10-19 Crescendo Biologics Limited Chimeric antigen receptor that binds mesothelin
IL317811A (en) 2022-07-25 2025-02-01 Interius Biotherapeutics Inc Mutated polypeptides, compositions containing them and uses thereof
CN116003628A (zh) * 2022-08-15 2023-04-25 南京博安生物技术有限公司 靶向人dll3抗原的全人源特异性嵌合抗原受体及其应用
CN116813784B (zh) * 2023-05-17 2024-03-01 星奕昂(上海)生物科技有限公司 靶向dll3的抗体及其应用
AU2024347905A1 (en) * 2023-09-26 2026-04-02 Legend Biotech Ireland Limited Dll3 binding moieties and uses thereof
WO2025082340A1 (zh) * 2023-10-16 2025-04-24 上海先博生物科技有限公司 一种靶向δ样配体3的CAR及应用
GB202402048D0 (en) 2024-02-14 2024-03-27 Bivictrix Ltd Therapeutic antibodies
GB202402046D0 (en) 2024-02-14 2024-03-27 Bivictrix Ltd Therapeutic antibodies
WO2025202653A1 (en) 2024-03-27 2025-10-02 Ucl Business Ltd T-cell therapy targetting mutant calreticulin
WO2026039940A1 (zh) * 2024-08-19 2026-02-26 南京博安生物技术有限公司 一种增强型靶向dll3蛋白的嵌合抗原受体和突变体以及应用
GB202412771D0 (en) 2024-08-30 2024-10-16 Cambridge Entpr Ltd Therapeutic molecules

Family Cites Families (31)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4946778A (en) 1987-09-21 1990-08-07 Genex Corporation Single polypeptide chain binding molecules
US5260203A (en) 1986-09-02 1993-11-09 Enzon, Inc. Single polypeptide chain binding molecules
ATE87659T1 (de) 1986-09-02 1993-04-15 Enzon Lab Inc Bindungsmolekuele mit einzelpolypeptidkette.
US6319494B1 (en) 1990-12-14 2001-11-20 Cell Genesys, Inc. Chimeric chains for receptor-associated signal transduction pathways
IL104570A0 (en) 1992-03-18 1993-05-13 Yeda Res & Dev Chimeric genes and cells transformed therewith
US5834266A (en) 1993-02-12 1998-11-10 President & Fellows Of Harvard College Regulated apoptosis
US5830462A (en) 1993-02-12 1998-11-03 President & Fellows Of Harvard College Regulated transcription of targeted genes and other biological events
US5869337A (en) 1993-02-12 1999-02-09 President And Fellows Of Harvard College Regulated transcription of targeted genes and other biological events
US20030036654A1 (en) 1994-08-18 2003-02-20 Holt Dennis A. Synthetic multimerizing agents
US5827642A (en) 1994-08-31 1998-10-27 Fred Hutchinson Cancer Research Center Rapid expansion method ("REM") for in vitro propagation of T lymphocytes
CA2406864A1 (en) 2000-02-24 2001-08-30 Life Technologies Corporation Simultaneous stimulation and concentration of cells
US6867041B2 (en) 2000-02-24 2005-03-15 Xcyte Therapies, Inc. Simultaneous stimulation and concentration of cells
US6797514B2 (en) 2000-02-24 2004-09-28 Xcyte Therapies, Inc. Simultaneous stimulation and concentration of cells
CA2427858A1 (en) * 2000-11-03 2002-05-10 University Of Vermont And State Agricultural College Compositions for inhibiting grb7
US20100196336A1 (en) 2006-05-23 2010-08-05 Dongsu Park Modified dendritic cells having enhanced survival and immunogenicity and related compositions and methods
WO2011146862A1 (en) 2010-05-21 2011-11-24 Bellicum Pharmaceuticals, Inc. Methods for inducing selective apoptosis
PH12013501201A1 (en) 2010-12-09 2013-07-29 Univ Pennsylvania Use of chimeric antigen receptor-modified t cells to treat cancer
AU2012209103B2 (en) 2011-01-26 2015-12-03 Takeda Pharmaceutical Company Limited Methods and compositions for the synthesis of multimerizing agents
CN110200997A (zh) 2011-03-23 2019-09-06 弗雷德哈钦森癌症研究中心 用于细胞免疫治疗的方法和组合物
WO2013059593A1 (en) * 2011-10-20 2013-04-25 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Anti-cd22 chimeric antigen receptors
PE20190658A1 (es) * 2012-02-24 2019-05-08 Abbvie Stemcentrx Llc Moduladores y metodos de empleo novedosos
EP4303232A3 (en) 2013-02-15 2024-04-17 The Regents of The University of California Chimeric antigen receptor and methods of use thereof
WO2014151960A2 (en) 2013-03-14 2014-09-25 Bellicum Pharmaceuticals, Inc. Methods for controlling t cell proliferation
WO2015017214A1 (en) 2013-07-29 2015-02-05 Bluebird Bio, Inc. Multipartite signaling proteins and uses thereof
US10287354B2 (en) 2013-12-20 2019-05-14 Novartis Ag Regulatable chimeric antigen receptor
JP2017505819A (ja) 2014-02-04 2017-02-23 カイト ファーマ インコーポレイテッドＫｉｔｅ Ｐｈａｒｍａ， Ｉｎｃ Ｂ細胞悪性腫瘍及び他のがんの治療に有用な自己ｔ細胞を産生する方法、並びにその組成物
US10934346B2 (en) 2014-02-14 2021-03-02 Bellicum Pharmaceuticals, Inc. Modified T cell comprising a polynucleotide encoding an inducible stimulating molecule comprising MyD88, CD40 and FKBP12
MA41613A (fr) * 2015-02-23 2018-01-02 Abbvie Stemcentrx Llc Récepteurs antigéniques chimériques anti-dll3 et procédés d'utilisation desdits récepteurs
TWI793062B (zh) * 2015-07-31 2023-02-21 德商安美基研究（慕尼黑）公司 Ｄｌｌ３及ｃｄ３抗體構築體
MY210545A (en) * 2016-04-01 2025-09-30 Kite Pharma Inc Chimeric receptors to flt3 and methods of use thereof
CN107400168B (zh) * 2017-07-18 2020-02-07 深圳市免疫基因治疗研究院 一种基于cd117的嵌合抗原受体及其应用

Also Published As

Publication number Publication date
SG11202009923TA (en) 2020-11-27
CO2020013392A2 (es) 2020-11-10
PH12020551671A1 (en) 2021-06-07
BR112020020857A2 (pt) 2021-01-19
TWI842703B (zh) 2024-05-21
JP7479290B2 (ja) 2024-05-08
CL2023000895A1 (es) 2023-11-03
SA520420301B1 (ar) 2024-08-05
JOP20200259A1 (ar) 2020-10-11
WO2019200007A1 (en) 2019-10-17
KR102951376B1 (ko) 2026-04-13
CN112334193A (zh) 2021-02-05
EP3773912A1 (en) 2021-02-17
US20210163621A1 (en) 2021-06-03
KR20210018797A (ko) 2021-02-18
MX2020010753A (es) 2021-01-29
CL2020002613A1 (es) 2020-12-28
TW202011999A (zh) 2020-04-01
JP2021520788A (ja) 2021-08-26
ZA202006943B (en) 2025-08-27
CR20200539A (es) 2021-07-01
CA3095920A1 (en) 2019-10-17
CL2023000896A1 (es) 2023-11-03
IL277735A (en) 2020-11-30
US12012462B2 (en) 2024-06-18
AU2019251473A1 (en) 2020-10-22
AU2026200393A1 (en) 2026-04-09
MY203383A (en) 2024-06-26
MA52203A (fr) 2021-02-17
EA202092417A1 (ru) 2021-01-26
UY38182A (es) 2019-10-31
PE20211396A1 (es) 2021-07-27
UA129466C2 (uk) 2025-05-07

Similar Documents

Publication Publication Date Title
AR114283A1 (es) Receptores quiméricos de dll3 y métodos para su uso
CL2022001873A1 (es) Receptores quiméricos y metodos de uso de los mismos
CO2018011804A2 (es) Receptores quiméricos de flt3 y métodos de uso de los mismos
CO2020012347A2 (es) Anticuerpos anti-hla-g y usos de los mismos.
EA201691473A1 (ru) Биспецифические анти-il-13/il-17 антитела и их применение
EA201791029A1 (ru) Антитела против интерлейкина-33 и их применение
MX390920B (es) Moléculas de unión a lag-3 y métodos de uso de las mismas.
MX385585B (es) Anticuerpos anti-c10orf54 y usos de los mismos.
PH12016501366A1 (en) Novel anti-baff antibodies
EA201600473A1 (ru) ГУМАНИЗИРОВАННЫЕ АНТИТЕЛА К Tau(PS422) И СПОСОБЫ ПРИМЕНЕНИЯ
MX379396B (es) Conjugados de pirrolobenzodiazepina y anticuerpo.
CL2024004076A1 (es) Receptores quiméricos de steap1 y métodos de uso de los mismos
EA201992027A1 (ru) Водный состав антитела против pd-l1
CO2019013718A2 (es) Anticuerpos anti-trkb
JOP20200295A1 (ar) أجسام أحادية النوعية ومتعددة النوعية مضادة لـ tmeff2 المضاد واستخداماتها
MX2018007818A (es) Anticuerpos dirigidos contra upk1b novedosos y metodos para su uso.
EA202092508A1 (ru) Составы на основе антител к pd-l1 человека
BR112016022013A2 (pt) anticorpos monoclonais para fator de crescimento e diferenciação 15 (gdf-15) e usos dos mesmos para tratamento de caquexia do câncer e câncer
EA201892257A1 (ru) Анти-cd3 антитела и способы применения